ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Lignende værker

• Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
  af: Carbognin, Luisa, et al.
  Udgivet: (2015)
• Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
  af: Bria, Emilio, et al.
  Udgivet: (2015)
• Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
  af: Carbognin, Luisa, et al.
  Udgivet: (2016)
• MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy
  af: Pilotto, Sara, et al.
  Udgivet: (2017)
• Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
  af: Zito Marino, Federica, et al.
  Udgivet: (2020)